Revolution Medicines Advances Pancreatic Cancer Trial with Daraxonrasib
Event summary
- Revolution Medicines initiated Phase 3 clinical trial RASolute 303 on April 2, 2026.
- The trial evaluates daraxonrasib as a monotherapy and in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC).
- The trial will enroll patients irrespective of tumor RAS genotype and assess progression-free survival and overall survival as primary endpoints.
- Daraxonrasib is one of four Phase 3 trials Revolution Medicines is currently conducting, the others targeting NSCLC.
The big picture
Pancreatic cancer represents a significant unmet medical need with a dismal five-year survival rate of only 3%. Revolution Medicines' strategy of targeting RAS-addicted cancers, which account for over 90% of PDAC cases, positions daraxonrasib as a potential breakthrough therapy. The trial's design, testing both monotherapy and combination approaches, reflects a cautious yet ambitious approach to drug development in a challenging therapeutic area.
What we're watching
- Clinical Efficacy
- The trial's success hinges on daraxonrasib demonstrating a statistically significant improvement in progression-free survival and overall survival compared to the standard of care, a challenging hurdle given the aggressive nature of PDAC.
- Combination Therapy
- The inclusion of combination therapy with gemcitabine and nab-paclitaxel will reveal whether daraxonrasib can effectively synergize with existing treatments, or if it encounters resistance mechanisms.
- Genotype Independence
- Given the trial's enrollment of patients irrespective of RAS genotype, the data will reveal whether daraxonrasib's efficacy is consistent across different RAS mutations or if specific genotypes exhibit greater responsiveness.
Related topics